MUMBAI, Sept 29 (Reuters) – India’s Sun Pharmaceutical Industries is planning to raise around 100 billion rupees ($1.04 billion) via a upee-denominated debt sale to partly fund a bridge loan it took to acquire US healthcare firm Organon & Co., three sources said on Tuesday.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.